PixarBio CEO Frank Reynolds Executive Interview

PixarBio CEO/CSO Frank Reynolds Discusses His 60 US-INTL Neurological Patent Filings from 2006-20

President Trump Declares The Opioid Crisis a Public Health Emergency


PixarBio is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain. PixarBio researches and develops targeted delivery systems for drugs, cells, or biologics to treat pain, epilepsy, Parkinson’s disease, and spinal cord injury. Our lead product platform, NeuroRelease™, has achieved sustained therapeutic release of non-opiate drugs for post-operative, acute and chronic pain in pre-clinical models.

PixarBio April 2018 Update

PixarBio Corporation Letter to Shareholders

The Story behind PixarBio’s Termination of the InVivo Therapeutics Deal

Stock Quote